A Paradigm Shift in Screening for Barrett's Esophagus: The BEST Is Yet to Come

Affiliations

¹ H.H. Chao Comprehensive Digestive Disease Center, University of California Irvine, Orange, California.
² Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Comment

Jennifer M Kolb et al. Gastroenterology. 2021 Jan.

. 2021 Jan;160(1):467-469.

doi: 10.1053/j.gastro.2020.11.024. Epub 2020 Nov 19.

¹ H.H. Chao Comprehensive Digestive Disease Center, University of California Irvine, Orange, California.
² Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

No abstract available

Comment on

Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC, di Pietro M, O'Donovan M, Maroni R, Muldrew B, Debiram-Beecham I, Gehrung M, Offman J, Tripathi M, Smith SG, Aigret B, Walter FM, Rubin G; BEST3 Trial team; Sasieni P. Fitzgerald RC, et al. Lancet. 2020 Aug 1;396(10247):333-344. doi: 10.1016/S0140-6736(20)31099-0. Lancet. 2020. PMID: 32738955 Free PMC article. Clinical Trial.